Long-Term Data Confirm TH Benefit in Early HER2-Positive Breast Cancer
This video highlights 7-year follow-up data from the APT trial, which studied adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses 7-year follow-up data of the APT trial, which studied adjuvant paclitaxel/trastuzumab (TH) in early-stage patients with node-negative, HER2-positive breast cancer.
Tolaney presented the study results (abstract 511) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.
Recent Videos
Related Content
Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care
Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO
March 10th 2025Podcast
Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.
